TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 BABA
Alibaba
-- 124.730 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 
NEWS
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Quince Therapeutics (Nasdaq: QNCX) announced the publication of Phase 3 ATTeST clinical trial data in The Lancet Neurology, evaluating EryDex for treating Ataxia-Telangiectasia (A-T). The study, involving 175 participants across 22 institutions in 12 countries, demonstrated a favorable safety profile and positive effects in patients aged 6-9 years.
Key findings include:
No serious safety concerns typically associated with chronic corticosteroid use
Statistically significant reduction in neurological symptoms in 6-9 year olds receiving high-dose EryDex
Potential treatment delays due to COVID-19 pandemic affected overall results
Quince has initiated the pivotal Phase 3 NEAT study under FDA Special Protocol Assessment, with topline results expected in Q4 2025.
Key findings include:
No serious safety concerns typically associated with chronic corticosteroid use
Statistically significant reduction in neurological symptoms in 6-9 year olds receiving high-dose EryDex
Potential treatment delays due to COVID-19 pandemic affected overall results
Quince has initiated the pivotal Phase 3 NEAT study under FDA Special Protocol Assessment, with topline results expected in Q4 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8181
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call